Q2 2024 BioLife Solutions Inc Earnings Call Transcript
Key Points
- BioLife Solutions Inc (BLFS) reported an 11% sequential increase in cell processing revenue and a 6% sequential increase in total revenue for Q2 2024.
- The company has increased its full-year revenue guidance to $99 million to $101 million, reflecting an overall growth of 5% to 8%.
- Adjusted gross margin improved to 52% in Q2 2024, up from 45% in the prior year, due to product mix, operational efficiencies, and higher capacity utilization.
- BioLife Solutions Inc (BLFS) has a market share exceeding 70% in commercially sponsored clinical trials in the US, with significant involvement in Phase 2 and Phase 3 trials.
- The company is well-positioned to benefit from easing industry headwinds and the maturation of the cell and gene therapy (CGT) industry, with strong relationships with commercial therapy customers.
- Q2 2024 revenue from continuing operations decreased by 3% year-over-year, primarily due to a 4% decrease in the cell processing platform.
- The company's GAAP net loss increased to $7.1 million in Q2 2024, compared to $5.5 million in the prior year, partly due to a $4.1 million write-off of an investment.
- BioLife Solutions Inc (BLFS) experienced a sequential cash decrease of $9.2 million, driven by cash outflows related to the divestiture of Global Cooling.
- The biostorage services platform guidance was adjusted to the lower end of the prior range, indicating potential challenges in achieving higher growth.
- The company is still in the process of divesting its Custom BioGenic Systems (CBS) unit, which is a drag on margins despite generating positive adjusted EBITDA.
Good afternoon, and welcome to the BioLife Solutions Q2 2024 shareholder and analyst conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead.
Thank you, operator. Good afternoon, everyone, and thank you for joining the BioLife Solutions 2024 second quarter earnings conference call. On today's call, we will cover business highlights and financial performance for the quarter and provide an update on our full year 2024 revenue guidance.
Earlier today, we issued a press release announcing our financial results and operational highlights for the second quarter of 2024, which is available at biolifesolutions.com. As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC filings.
These statements speak only as of the date
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
